This Article Full Text Full Text (PDF) All Versions of this Article: 90/2/800    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Minniti, G. Articles by Brada, M. Search for Related Content PubMed PubMed Citation Articles by Minniti, G. Articles by Brada, M. Related Collections Pediatric Endocrinology Endocrine Oncology

Risk of Second Brain Tumor after Conservative Surgery and Radiotherapy for Pituitary Adenoma: Update after an Additional 10 Years

Neuro-Oncology Unit (G.M., D.T., A.G., M.B.), Computing Department (S.A.), The Royal Marsden NHS Foundation Trust, and Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research (D.T., M.B.), Sutton, Surrey SM2 5PT, United Kingdom

Address all correspondence and requests for reprints to: Dr. Michael Brada, Institute of Cancer Research and Royal Marsden National Health Service Trust, Downs Road, Sutton, Surrey, United Kingdom SM2 5PT. E-mail: michael.brada{at}icr.ac.uk.

We assessed the risk of second brain tumors in a cohort of patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Four hundred and twenty-six patients (United Kingdom residents) with pituitary adenomas received radiotherapy at the Royal Marsden Hospital (RMH) between 1962 and 1994. They were followed up for 5749 person-years. The cumulative incidence of second intracranial tumors and systemic malignancy was compared with population incidence rates through the Thames Cancer Registry and the National Health Service Central Register (previously OPCS) to record death and the potential causes. Eleven patients developed a second brain tumor, including five meningiomas, four high grade astrocytomas, one meningeal sarcoma, and one primitive neuroectodermal tumor. The cumulative risk of second brain tumors was 2.0% [95% confidence interval (CI), 0.9–4.4%] at 10 yr and 2.4% (95% CI, 1.2–5.0%) at 20 yr, measured from the date of radiotherapy. The relative risk of second brain tumor compared with the incidence in the normal population was 10.5 (95% CI, 4.3–16.7). The relative risk was 7.0 for neuroepithelial and 24.3 for meningeal tumors. The relative risks were 24.2 (95% CI, 4.8–43.5), 2.9 (95% CI, 0–8.5), and 28.6 (95% CI, 0.6–56.6) during the intervals 5–9, 10–19, and more than 20 yr after radiotherapy (four cases occurred >20 yr after treatment). There was no evidence of excess risk of second systemic malignancy. An additional 10-yr update confirmed our previous report of an increased risk of second brain tumors in patients with pituitary adenoma treated with surgery and radiotherapy. The 2.4% risk at 20 yr remains low and should not preclude the use of radiotherapy as an effective treatment option. However, an increased risk of second brain tumors continues beyond 20 and 30 yr after treatment.

This article has been cited by other articles:

				B. W. Scheithauer, A. I. Silva, K. Kattner, J. Seibly, A. M. Oliveira, and K. Kovacs Synovial sarcoma of the sellar region Neuro-oncol, October 1, 2007; 9(4): 454 - 459. [Abstract] [Full Text] [PDF]

				C-H Toh, H-F Wong, S-M Jung, and A-M Wong Radiation-induced skull base leiomyosarcoma presenting with intracerebral haemorrhage Br. J. Radiol., September 1, 2007; 80(957): e212 - e215. [Abstract] [Full Text] [PDF]

				S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				O. M. Dekkers, A. M. Pereira, F. Roelfsema, J. H. C. Voormolen, K. J. Neelis, M. A. Schroijen, J. W. A. Smit, and J. A. Romijn Observation Alone after Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1796 - 1801. [Abstract] [Full Text] [PDF]

				R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, and G. Pagani Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1397 - 1403. [Abstract] [Full Text] [PDF]